{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T10:58:11Z","timestamp":1769425091020,"version":"3.49.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009610","name":"Pontificia Universidad Cat\u00f3lica de Chile","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","award":["1171047"],"award-info":[{"award-number":["1171047"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.colsurfb.2023.113420","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T20:50:46Z","timestamp":1687294246000},"page":"113420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Increased delivery and cytotoxicity of doxorubicin in HeLa cells using the synthetic cationic peptide pEM-2 functionalized liposomes"],"prefix":"10.1016","volume":"228","author":[{"given":"Diego","family":"Salas Sanzana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Flores Fa\u00fandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Mel\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Soto-Arriaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.colsurfb.2023.113420_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.tips.2015.03.005","article-title":"Anthracyclines\/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms","volume":"36","author":"Rochette","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.colsurfb.2023.113420_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrclinonc.2015.171","article-title":"Breast cancer therapy associated cardiovascular disease","volume":"13","author":"Zagar","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.colsurfb.2023.113420_bib3","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.1038\/srep44735","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2023.113420_bib4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1517\/14712598.4.1.35","article-title":"Microspheres for controlled release drug delivery","volume":"4","author":"Varde","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.colsurfb.2023.113420_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ijpharm.2015.09.014","article-title":"Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach","volume":"495","author":"Makwana","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2023.113420_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/0975-7406.130965","article-title":"Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues","volume":"6","author":"Madaan","year":"2014","journal-title":"J. Pharm. Bioallied. Sci."},{"key":"10.1016\/j.colsurfb.2023.113420_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jconrel.2011.12.012","article-title":"Polymeric micelles drug delivery system in oncology","volume":"159","author":"Gong","year":"2012","journal-title":"J. Control, Release"},{"key":"10.1016\/j.colsurfb.2023.113420_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.colsurfb.2023.113420_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10611869609015970","article-title":"Liposomal doxorubicin","volume":"4","author":"Tardi","year":"1996","journal-title":"J. Drug Target"},{"key":"10.1016\/j.colsurfb.2023.113420_bib10","first-page":"3366","article-title":"Influence of lipid-composition on the antitumor-activity exerted by doxorubicin-containing liposomes in a rat solid tumor-model","volume":"47","author":"Storm","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.colsurfb.2023.113420_bib11","first-page":"1817","article-title":"Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration","volume":"42","author":"Rahman","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/j.colsurfb.2023.113420_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0277-5379(82)90060-8","article-title":"Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes","volume":"18","author":"Olson","year":"1982","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.colsurfb.2023.113420_bib13","first-page":"4734","article-title":"Liposomes as in vivo carriers of adriamycin-reduced cardiac uptake and preserved anti-tumor activity in mice","volume":"42","author":"Gabizon","year":"1982","journal-title":"Cancer Res"},{"key":"10.1016\/j.colsurfb.2023.113420_bib14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00273522","article-title":"Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin","volume":"23","author":"Balazsovits","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.colsurfb.2023.113420_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0304-3835(90)90212-G","article-title":"Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the sc115 murine mammary-tumor","volume":"53","author":"Mayer","year":"1990","journal-title":"Cancer Lett."},{"key":"10.1016\/j.colsurfb.2023.113420_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","article-title":"Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin","volume":"232","author":"Petersen","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2023.113420_bib17","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1039\/c2md20153d","article-title":"Engineering of peglayted camptothecin into core-shell nanomicelles for improving solubility, stability and combination delivery","volume":"3","author":"Dong","year":"2012","journal-title":"MedChemComm"},{"key":"10.1016\/j.colsurfb.2023.113420_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.colsurfb.2023.113420_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.colsurfb.2023.113420_bib20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/1061186X.2018.1527337","article-title":"Liposome: composition, characterization, preparation, and recent innovation in clinical applications","volume":"27","author":"Ahmed","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.colsurfb.2023.113420_bib21","first-page":"147","volume":"147","author":"Laouini","year":"2012","journal-title":"Prep., Charact. Appl. liposomes: State Art., J. Colloid Sci. Biotechnol."},{"key":"10.1016\/j.colsurfb.2023.113420_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0076-6879(05)91004-5","article-title":"The liposomal formulation of doxorubicin","volume":"391","author":"Abraham","year":"2005","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.colsurfb.2023.113420_bib23","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.nano.2017.02.008","article-title":"Tumor accumulation of liposomal doxorubicin in three murine models: optimizing delivery efficiency","volume":"13","author":"Dawidczyk","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2023.113420_bib24","first-page":"335","article-title":"Doxil\u00ae - The first FDA-approved nano-drug: from an idea to a product. handbook of harnessing biomaterials in nanomedicine: preparation","author":"Barenholz","year":"2012","journal-title":"Toxic., Appl., Pan Stand. Publ. Singap."},{"key":"10.1016\/j.colsurfb.2023.113420_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/bpb.b16-00624","article-title":"Liposomal delivery systems: design optimization and current applications","volume":"40","author":"Abu-Lila","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.colsurfb.2023.113420_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014The first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2023.113420_bib27","first-page":"891","article-title":"Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes","volume":"52","author":"Gabizon","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.colsurfb.2023.113420_bib28","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.nano.2015.06.007","article-title":"In vitro experiments showing enhanced release of doxorubicin from Doxil(R) in the presence of ammonia may explain drug release at tumor site","volume":"11","author":"Silverman","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2023.113420_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0005-2736(91)90246-5","article-title":"Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo","volume":"1066","author":"Allen","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.colsurfb.2023.113420_bib30","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1208\/s12249-019-1385-0","article-title":"Dual-ligand modification of PEGylated liposomes used for targeted doxorubicin delivery to enhance anticancer efficacy","volume":"20","author":"Li","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.colsurfb.2023.113420_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijpharm.2009.01.023","article-title":"Targeted delivery of doxorubicin using stealth liposomes modified with transferrin","volume":"373","author":"Li","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2023.113420_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2217\/nnm.10.30","article-title":"Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein","volume":"5","author":"Wang","year":"2010","journal-title":"Nanomed. (Lond. )"},{"key":"10.1016\/j.colsurfb.2023.113420_bib33","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1038\/s41467-019-11593-z","article-title":"Brain-targeted drug delivery by manipulating protein corona functions","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.colsurfb.2023.113420_bib34","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/24\/40\/405101","article-title":"Tumor-penetrating peptide functionalization enhances the anti- glioblastoma effect of doxorubicin liposomes","volume":"24","author":"Yang","year":"2013","journal-title":"Nanotechnology"},{"key":"10.1016\/j.colsurfb.2023.113420_bib35","doi-asserted-by":"crossref","first-page":"7348","DOI":"10.1167\/iovs.12-9955","article-title":"EphA2 targeted doxorubicin stealth liposomes as a therapy system for choroidal neovascularization in rats","volume":"53","author":"Wang","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.colsurfb.2023.113420_bib36","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/10717544.2011.567310","article-title":"Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements","volume":"18","author":"Koren","year":"2011","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2023.113420_bib37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijpharm.2015.04.059","article-title":"Doxorubicin liposomes as an investigative model to study the skin permeation of nanocarriers","volume":"489","author":"Boakye","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2023.113420_bib38","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.2147\/IJN.S150017","article-title":"Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance","volume":"13","author":"Haghiralsadat","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.colsurfb.2023.113420_bib39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejpb.2012.12.021","article-title":"Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity","volume":"84","author":"Biswas","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.colsurfb.2023.113420_bib40","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1007\/s11095-015-1746-7","article-title":"Enhanced specificity and drug delivery in tumors by cRGD-anchoring thermosensitive liposomes","volume":"32","author":"Dicheva","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.colsurfb.2023.113420_bib41","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.7150\/thno.14302","article-title":"HER2 targeting peptides screening and applications in tumor imaging and drug delivery","volume":"6","author":"Geng","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.colsurfb.2023.113420_bib42","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.colsurfb.2023.113420_bib43","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3109\/10717544.2015.1040527","article-title":"Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma","volume":"23","author":"Yuan","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2023.113420_bib44","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s11095-014-1418-z","article-title":"Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo","volume":"31","author":"Zhu","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.colsurfb.2023.113420_bib45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2013.02.020","article-title":"Octa- arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer","volume":"335","author":"Biswas","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.colsurfb.2023.113420_bib46","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.2147\/DDDT.S317454","article-title":"Dual-functional peptide driven liposome codelivery system for efficient treatment of doxorubicin-resistant breast cancer","volume":"15","author":"Ahmed","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.colsurfb.2023.113420_bib47","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/203639","article-title":"Antitumoral activity of snake venom proteins: new trends in cancer therapy","volume":"2014","author":"Calderon","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.colsurfb.2023.113420_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/391389","article-title":"Antitumoral potential of tunisian snake venoms secreted phospholipases A2","volume":"2013","author":"Zouari-Kessentini","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.colsurfb.2023.113420_bib49","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2174\/092986609788923356","article-title":"The phospholipase A2 homologues of snake venoms: biological activities and their possible adaptive roles","volume":"16","author":"Lomonte","year":"2009","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.colsurfb.2023.113420_bib50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.toxicon.2007.08.007","article-title":"Systemic and local myotoxicity induced by snake venom group II phospholipases A2: Comparison between crotoxin, crotoxin B and a Lys49 PLA2 homologue","volume":"51","author":"Gutierrez","year":"2008","journal-title":"Toxicon"},{"key":"10.1016\/j.colsurfb.2023.113420_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109846","article-title":"Synergism between basic Asp49 and Lys49 phospholipase A2 myotoxins of viperid snake venom in nitro and in vivo","volume":"9","author":"Mora-Obando","year":"2014","journal-title":"PLOS One"},{"key":"10.1016\/j.colsurfb.2023.113420_bib52","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.tiv.2007.04.010","article-title":"Cytotoxicity induced in myotubes by a Lys49 Phospholipase A2 homologue from the venom of the snake Bothrops asper: Evidence of rapid plasma membrane damage and a dual role for extracellular calcium","volume":"21","author":"Villalobos","year":"2007","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.colsurfb.2023.113420_bib53","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.toxicon.2003.11.008","article-title":"An overview of lysine-49 phospholipase A2 myotoxins from crotalid snake venoms and their structural determinants of myotoxic action","volume":"42","author":"Lomonte","year":"2003","journal-title":"Toxicon"},{"key":"10.1016\/j.colsurfb.2023.113420_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/S0041-0101(01)00141-6","article-title":"Identification of the myotoxic site of the Lys49 phospholipase A(2) from Agkistrodon piscivorus piscivorus snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities","volume":"39","author":"N\u00fa\u00f1ez","year":"2001","journal-title":"Toxicon"},{"key":"10.1016\/j.colsurfb.2023.113420_bib55","doi-asserted-by":"crossref","first-page":"29867","DOI":"10.1016\/S0021-9258(18)43961-0","article-title":"Neutralizing interaction between heparins and myotoxin II, a lysine 49 phospholipase A2 from Bothrops asper snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling","volume":"269","author":"Lomonte","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.colsurfb.2023.113420_bib56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.cellbi.2006.11.007","article-title":"Antitumor effects of cationic synthetic peptides derived from Lys49 phospholipase A2 homologues of snake venoms","volume":"31","author":"Araya","year":"2007","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.colsurfb.2023.113420_bib57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0005-2736(86)90302-0","article-title":"Vesicles of variable sizes produced by a rapid extrusion procedure","volume":"858","author":"Mayer","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.colsurfb.2023.113420_bib58","first-page":"5","article-title":"Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential","volume":"812","author":"Hope","year":"1985","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.colsurfb.2023.113420_bib59","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0009-3084(86)90077-0","article-title":"Techniques for encapsulating bioactive agents into liposomes","volume":"40","author":"Mayer","year":"1986","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.colsurfb.2023.113420_bib60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0003-2697(80)90269-9","article-title":"Colorimetric determination of phospholipids with ammonium ferrothiocyanate","volume":"104","author":"Stewart","year":"1980","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.colsurfb.2023.113420_bib61","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1039\/C5OB02480C","article-title":"Simple and rapid quantification of phospholipids for supramolecular membrane transport assays","volume":"14","author":"Hein","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.colsurfb.2023.113420_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijpharm.2016.11.039","article-title":"Fabrication of liposomal doxorubicin exhibiting ultrasensitivity against phospholipase A2 for efficient pulmonary drug delivery to lung cancers","volume":"517","author":"Tagami","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2023.113420_bib63","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0014-5793(88)80854-8","article-title":"Protein immobilization on the surface of liposomes via carbodiimide activation in the presence of N- hydroxysulfosuccinimide","volume":"231","author":"Bogdanov","year":"1988","journal-title":"FEBS Lett."},{"key":"10.1016\/j.colsurfb.2023.113420_bib64","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1016\/j.bbamem.2012.08.008","article-title":"Interaction of gramicidin with DPPC\/DODAB bilayer fragment","volume":"1818","author":"Carvalho","year":"2012","journal-title":"Biochim. Et. Biophys. Acta"},{"key":"10.1016\/j.colsurfb.2023.113420_bib65","doi-asserted-by":"crossref","first-page":"18109","DOI":"10.1021\/acsomega.8b03016","article-title":"Antibody binding at the liposome-water interface: A FRET investigation toward a liposome-based assay","volume":"3","author":"Hoang","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.colsurfb.2023.113420_bib66","unstructured":"T. Riss, R. Moravec, A. Niles, Cell Viability Assays, [Updated 2016 Jul 1]. In: Markossian S., Grossman A., Brimacombe K., et al., editors. Assay Guidance Manual Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences 1 (2013) 1\u201310."},{"key":"10.1016\/j.colsurfb.2023.113420_bib67","article-title":"Liposomes as carriers of hydrophilic small molecule drugs: Strategies to enhance encapsulation and delivery","volume":"123","author":"Oliveira","year":"2014"},{"key":"10.1016\/j.colsurfb.2023.113420_bib68","doi-asserted-by":"crossref","unstructured":"A. Fritze, F. Hens, A. Kimpfler, R. Schubert, R. Peschka-Suss, Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient, Biochemica et Biophysica Acta 1758 (2006) 1633\u20131640.","DOI":"10.1016\/j.bbamem.2006.05.028"},{"key":"10.1016\/j.colsurfb.2023.113420_bib69","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0378-5173(99)00207-0","article-title":"Factors affecting the size distribution of liposomes produced by freeze-thaw extrusion","volume":"188","author":"Castile","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2023.113420_bib70","doi-asserted-by":"crossref","first-page":"22960","DOI":"10.3390\/ijms151222960","article-title":"Modulation of induced cytotoxicity of doxorubicin by using apoferritin and liposomal cages","volume":"15","author":"Gumulec","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.colsurfb.2023.113420_bib71","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10450-016-9767-z","article-title":"Zeta potential and surface charge of DPPC and DOPC liposomes in the presence of PLC enzyme","volume":"22","author":"Chibowski","year":"2016","journal-title":"Adsorption"},{"key":"10.1016\/j.colsurfb.2023.113420_bib72","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1006\/jcis.1998.5715","article-title":"Influence of size on electrokinetic behavior of phosphatidylserine and phosphatidilethanolamine lipid vesicles","volume":"206","author":"Roy","year":"1998","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.colsurfb.2023.113420_bib73","first-page":"330","article-title":"Original synthetic peptide variant against Candida albicans","volume":"20","author":"Murillo","year":"2007","journal-title":"Rev. Esp. Quimioter."},{"key":"10.1016\/j.colsurfb.2023.113420_bib74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/10717540601098799","article-title":"Liposome formulation of paclitaxel with enhanced solubility and stability","volume":"14","author":"Yang","year":"2007","journal-title":"Drug Deliv."},{"key":"10.1016\/j.colsurfb.2023.113420_bib75","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijpharm.2012.01.045","article-title":"Physico-chemical characteristics of methotrexate entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment","volume":"427","author":"Srisuk","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.colsurfb.2023.113420_bib76","first-page":"103","article-title":"A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems, Nanotechnology","volume":"8","author":"Kaminskas","year":"2012","journal-title":"Biol., Med."},{"key":"10.1016\/j.colsurfb.2023.113420_bib77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jconrel.2013.08.034","article-title":"Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: Evaluated by in vitro\/in vivo live cell imaging","volume":"172","author":"Seynhaeve","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.colsurfb.2023.113420_bib78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.seminoncol.2004.08.002","article-title":"Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies","volume":"31","author":"Vail","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.colsurfb.2023.113420_bib79","doi-asserted-by":"crossref","first-page":"10530","DOI":"10.1038\/s41598-020-67207-y","article-title":"Efficient uptake and retention of iron oxide-based nanoparticles in HeLa cells leads to an effective intracellular delivery of doxorubicin","volume":"10","author":"Popescu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.colsurfb.2023.113420_bib80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/08982104.2019.1634724","article-title":"Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect","volume":"30","author":"Ahmed","year":"2020","journal-title":"J. Liposome Res."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776523002989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776523002989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:21:28Z","timestamp":1760527288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776523002989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":80,"alternative-id":["S0927776523002989"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113420","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased delivery and cytotoxicity of doxorubicin in HeLa cells using the synthetic cationic peptide pEM-2 functionalized liposomes","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2023.113420","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113420"}}